ABUS
Price
$3.34
Change
+$0.10 (+3.09%)
Updated
Apr 24 closing price
Capitalization
639.54M
6 days until earnings call
ARRY
Price
$4.56
Change
+$0.23 (+5.31%)
Updated
Apr 24 closing price
Capitalization
2.22B
11 days until earnings call
Ad is loading...

ABUS vs ARRY

Header iconABUS vs ARRY Comparison
Open Charts ABUS vs ARRYBanner chart's image
Arbutus Biopharma
Price$3.34
Change+$0.10 (+3.09%)
Volume$774.78K
Capitalization639.54M
Array Technologies
Price$4.56
Change+$0.23 (+5.31%)
Volume$4.04M
Capitalization2.22B
ABUS vs ARRY Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. ARRY commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Buy and ARRY is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ABUS: $3.34)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green while.

  • ABUS’s FA Score: 0 green, 5 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 6 TA indicator(s) are bullish while ARRY’s TA Score has 5 bullish TA indicator(s).

  • ABUS’s TA Score: 6 bullish, 3 bearish.
  • ARRY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than ARRY.

Price Growth

ABUS (@Biotechnology) experienced а +6.03% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ABUS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARRY($2.22B) has a higher market cap than ABUS($640M). ABUS YTD gains are higher at: 2.141 vs. ARRY (-24.503). ARRY has higher annual earnings (EBITDA): 276M vs. ABUS (-75.14M). ARRY has more cash in the bank: 249M vs. ABUS (128M). ABUS has less debt than ARRY: ABUS (1.45M) vs ARRY (730M). ARRY has higher revenues than ABUS: ARRY (1.58B) vs ABUS (6.74M).
ABUSARRYABUS / ARRY
Capitalization640M2.22B29%
EBITDA-75.14M276M-27%
Gain YTD2.141-24.503-9%
P/E RatioN/A26.23-
Revenue6.74M1.58B0%
Total Cash128M249M51%
Total Debt1.45M730M0%
FUNDAMENTALS RATINGS
ABUS vs ARRY: Fundamental Ratings
ABUS
ARRY
OUTLOOK RATING
1..100
1211
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
59100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
5791
P/E GROWTH RATING
1..100
10023
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (67) in the Biotechnology industry is in the same range as ARRY (98). This means that ABUS’s stock grew similarly to ARRY’s over the last 12 months.

ABUS's Profit vs Risk Rating (59) in the Biotechnology industry is somewhat better than the same rating for ARRY (100). This means that ABUS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ABUS's SMR Rating (95) in the Biotechnology industry is in the same range as ARRY (99). This means that ABUS’s stock grew similarly to ARRY’s over the last 12 months.

ABUS's Price Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for ARRY (91). This means that ABUS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ARRY's P/E Growth Rating (23) in the Biotechnology industry is significantly better than the same rating for ABUS (100). This means that ARRY’s stock grew significantly faster than ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSARRY
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 10 days ago
79%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BCBDX11.43N/A
N/A
BlackRock Global Dividend Inv C
VBAIX45.43N/A
N/A
Vanguard Balanced Index I
TRSEX15.29N/A
N/A
Nuveen Quant Small Cap Equity Ret
STSGX10.70N/A
N/A
American Beacon Stephens Sm Cp Gr Inv
AGCVX16.99N/A
N/A
American Century Global Small Cap Inv

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with ARRY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+3.09%
ARRY - ABUS
43%
Loosely correlated
+5.31%
AXON - ABUS
42%
Loosely correlated
+2.39%
DNLI - ABUS
41%
Loosely correlated
+4.17%
IDYA - ABUS
41%
Loosely correlated
+1.33%
VTYX - ABUS
39%
Loosely correlated
+8.62%
More